905 studies found for:    "Carcinoma, Hepatocellular"
Show Display Options
Rank Status Study
21 Recruiting Proton Beam Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With Hepatocellular Carcinoma Exceeding San Francisco Criteria
Condition: Carcinoma, Hepatocellular
Interventions: Radiation: Proton Beam Radiotherapy;   Drug: Sorafenib
22 Completed A Study of Recombinant Vaccinia Virus to Treat Unresectable Primary Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Genetic: JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)
23 Recruiting Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Subjects With Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: MSC2156119J;   Drug: Sorafenib
24 Unknown  Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma;   Metastatic Hepatocellular Carcinoma
Intervention: Drug: Sorafenib with Capecitabine and Oxaliplatin
25 Completed TK-based Suicide Gene Therapy for Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Genetic: TK99UN
26 Recruiting c-Met Second-Line Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: MSC2156119J
27 Active, not recruiting Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
28 Withdrawn Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatocellular Cancer;   Hepatoma;   Liver Cancer
Interventions: Drug: Sorafenib;   Radiation: Conventional fractionation (2 Gy per day) external beam radiation therapy
29 Completed
Has Results
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin;   Drug: Doxorubicin/Placebo
30 Not yet recruiting TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma
Conditions: PHENYTOIN/SORAFENIB [VA Drug Interaction];   Carcinoma, Hepatocellular
Interventions: Procedure: TACE;   Drug: sorafenib combined with TACE
31 Recruiting Refametinib(BAY86-9766) in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Refametinib (BAY86-9766)
32 Active, not recruiting Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma;   Hepatoma
Interventions: Drug: sorafenib;   Procedure: LC Bead-TACE
33 Completed Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
34 Terminated Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Thalidomide(Thado)
35 Completed Phase II Trial of Capecitabine for the Treatment of Unresectable/ Metastatic or Advanced Hepatocellular Carcinoma(HCC)
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Capecitabine in HCC
36 Completed
Has Results
A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma
Condition: Carcinoma, Hepatocellular
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
37 Active, not recruiting Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
38 Unknown  Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging
Conditions: Carcinoma, Hepatocellular;   Cirrhosis
Intervention: Procedure: Liver transplantation
39 Recruiting Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Refametinib (BAY86-9766);   Drug: Sorafenib (BAY43-9006)
40 Withdrawn Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver
Conditions: Liver Cirrhosis;   Carcinoma, Hepatocellular
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years